Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer

British Journal of Cancer

Volumn 97, Issue 12, 2007, Pages 1613-1617

  Galli, L ^a   Fontana, A ^a   Galli, C ^a   Landi, L ^a   Fontana, E ^a   Antonuzzo, A ^a   Andreuccetti, M ^a   Aitini, E ^b   Barbieri, R ^b   Di Marsico, R ^a   Falcone, A ^a,c  

^a Azienda USL 6   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Docetaxel; Estramustine; Mitoxantrone; Prostate cancer; Sequential chemotherapy

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; HORMONE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LIVER TOXICITY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 37049020889     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604090     Document Type: Article

References (23)

1. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen independent prostate cancer. Ann Oncol 12: 1273-1279
2. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hades G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17: 3461-3467
3. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, Manente P (1997) Phase II study of estramustine oral etoposide and vinorelbine in hormone refractory prostate cancer. Am J Clin Oncol 20: 383-386
4. Font A, Murias A, Garcia Arroyo AF, Martin C, Areal J, Sanchez JJ, Santiago JA, Constenla M, Saladie JM, Rosell R (2005) Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 16: 419-424
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer Statistics 2006. CA Cancer J Clin 56: 106-130
6. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukaemia group B9182 study. J Clin Oncol 17: 2506-2513
7. Kreis W, Budman DR, Calabro A (1997) Unique synergism or antagonism of combinations of chemotherapeutics and hormonal agents in human prostate cancer cell lines. Br J Urol 79: 196-202
8. Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First and second line chemotherapy with docetaxel or mitoxantrone in patients with hormone refractory prostate cancer. Does sequence matter? Cancer 106: 1041-1046
9. Oudard S, Banu S, Beuzeboc B, Voog E, Dourthe LM, Hardy-Bessard AM, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM (2005) Multicenter randomized phase II study of two schedules of decetaxel, estramustine, and prednisone vs mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3343-3351
10. Petrylak DP, Shelton GB, England-Owen C (2000) Response and preliminary survival results of a phase II study of docetaxel (D) estramustine (E) in patients with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 19: 334a
11. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour RMC, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
12. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26(5 suppl 17): 14-18
13. Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300-318
14. Rosenberg JE, Weinberg VK, Kelly Wk (2006) Randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane resistant hormone refractory prostate cancer. Prostate Cancer Symposium February 24-26: abstract 253, pp 220
15. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and leukaemia group B. J Clin Oncol 19: 2509-2516
16. Segawa T, Kamoto T, Kinoshita H, Kunishima Y, Yoshimura K, Ito A, Takahashi T, Higashi S, Nakamura E, Nishiyama H, Ito N, Yamamoto S, Habuchi T, Ogawa O (2005) Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. Int J Clin Oncol 10: 333-337
17. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA (2002) Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94: 1457-1465
18. Sitki Copur MS, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, Norvell M, Muhvic J, Hake L, Wendt J (2001) Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 28(4 suppl 15): 16-21
19. Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ (2003) Phase II trial of paclitaxel, estramustine, etoposide and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98: 269-276
20. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone refractory prostate cancer. J Clin Oncol 17: 1664-1671
21. Stearns ME, Tew KD (1985) Antimicrotubule effects of estramustine, an antineoplastic tumor drug. Cancer Res 45: 3891-3897
22. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
23. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Armitage JR, Wilson JJ, Venner PM, Coppin CML, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764